CureVac Appoints Thaminda Ramanayake as New Chief Business Officer [Yahoo! Finance]
CureVac N.V. - Ordinary Shares (CVAC)
Company Research
Source: Yahoo! Finance
Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024. "Thaminda's extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas," said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. "Mr. Ramanayake is an accomplished strategist whose distinctive leadership and advisory expertise will make him an essential thought
Show less
Read more
Impact Snapshot
Event Time:
CVAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVAC alerts
High impacting CureVac N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CVAC
News
- CureVac (NASDAQ: CVAC) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.MarketBeat
- CureVac (NASDAQ: CVAC) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $12.00.MarketBeat
- CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]Yahoo! Finance
- CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update Accesswire
CVAC
Sec Filings
- 4/25/24 - Form 20-F
- 4/24/24 - Form 6-K
- 4/24/24 - Form 6-K
- CVAC's page on the SEC website